Recommendations

Here we present the recommendations for cardiomyopathy surveillance for childhood, adolescent and young adult cancer survivors treated with anthracycline chemotherapy and/or radiation to fields that include the heart (i.e. chest radiation).

General recommendation

General recommendation

Who needs cardiomyopathy surveillance after anthracycline chemotherapy?

Who needs surveillance A

 

Who needs cardiomyopathy surveillance after chest radiation?

Who needs surveillance R

 

Who needs cardiomyopathy surveillance after anthracycline chemotherapy and chest radiation?

Who needs surveillance A+R

What surveillance modality should be used?

What surveillance modality

At what frequency should surveillance be performed for high risk survivors?

What frequency high risk

 

At what frequency should surveillance be performed for moderate/low risk survivors?

What frequency low risk

 

At what frequency should surveillance be performed for survivors who are pregnant?

What frequency pregnant

What should be done when abnormalities are identified?

What should be done

What advice should be given regarding physical activity?

What advice
Green = strong recommendations to do; Yellow = moderate recommendation to do; Orange = weak recommendation to do; Red = recommendation not to do.

See The Lancet Oncology for the publication.